CBP/p300 bromodomain inhibition blocks GATA1 and MYC oncogene expression and induces chronic myeloid leukemia and lymphoma cell cycle arrest and growth inhibition 72. Here, MYC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.